Clinical Trials Logo

Filter by:
NCT ID: NCT05366855 Recruiting - Clinical trials for Generalized Pustular Psoriasis

Long-Term Safety and Efficacy of Imsidolimab (ANB019) in Subjects With Generalized Pustular Psoriasis

GEMINI2
Start date: April 21, 2022
Phase: Phase 3
Study type: Interventional

This is a Phase 3, long term extension study to evaluate the safety and efficacy of imsidolimab compared with placebo in adult subjects with generalized pustular psoriasis (GPP).

NCT ID: NCT05352893 Recruiting - Clinical trials for Generalized Pustular Psoriasis

Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Subjects With GPP

GEMINI1
Start date: April 14, 2022
Phase: Phase 3
Study type: Interventional

This is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of imsidolimab compared with placebo in adult subjects with generalized pustular psoriasis (GPP).

NCT ID: NCT05286411 Completed - Quality Improvement Clinical Trials

Evaluation of the Implementation of a Quality Improvement Program Through Morbidity and Mortality Reviews

Start date: January 1, 2019
Phase:
Study type: Observational

Morbidity and mortality reviews represent an opportunity to discuss adverse events and healthcare issues. Aim is to report the first experience of implementing a standardized procedure of morbidity and mortality reviews, and assess its impact on quality improvement.

NCT ID: NCT05244616 Recruiting - Clinical trials for Postoperative Recovery

Validation of the Arabic Version of the Postoperative Quality of Recovery Score 15 (Qor-15Ar)

Start date: February 16, 2022
Phase:
Study type: Observational

Anesthesia practice is not only centered on the patient's safety and well-being through the perioperative period but also on enhancing his overall recovery experience. This study aims to provide an adapted questionnaire for the Arabic-speaking population as a measuring tool of the quality of recovery after surgery.

NCT ID: NCT05200715 Recruiting - Uveitis Clinical Trials

AutoInflammatory Disease Alliance Registry (AIDA)

AIDA
Start date: August 6, 2020
Phase:
Study type: Observational [Patient Registry]

Autoinflammatory diseases (AID) are clinical entities characterized by recurrent inflammatory attacks in absence of infection, neoplasm or deregulation of the adaptive immune system. Among them, hereditary periodic syndromes, also known as monogenic AID, represent the prototype of this disease group, caused by mutations in genes involved in the regulation of innate immunity, inflammation and cell death. Based on recent experimental acquisitions in the field of monogenic AID, several immunologic disorders have been reclassified as polygenic/multifactorial AID, sharing pathogenetic and clinical features with hereditary periodic fevers. This has paved the way to new treatment targets for patients suffering from rare diseases of unknown origin, including Behçet's disease, Still disease, Schnitzler's disease, PFAPA (periodic fever, aphthous stomatitis, pharyngitis and cervical adenitis) syndrome, chronic recurrent multifocal osteomyelitis (CRMO), non-infectious uveitis and scleritis. Gathering information on such rare conditions is made difficult by the small number of patients, along with the difficulty of obtaining an accurate diagnosis in non-specialized clinical settings. In this context, the AIDA project promotes international collaboration among clinical centres to develop a permanent registry aimed at collecting demographic, genetic, clinical and therapeutic data of patients affected by monogenic and polygenic AID, in order to expand the current knowledge of these rare conditions.

NCT ID: NCT05059093 Recruiting - Clinical trials for Fetal Growth Restriction

Developing and Testing AI Models for Fetal Biometry and Amniotic Volume Assessment in Fetal Ultrasound Scans.

Start date: October 25, 2021
Phase:
Study type: Observational

Routine fetal ultrasound scan during the second trimester of the pregnancy is a low-cost, noninvasive screening modality that has been proven to lower fetal mortality by up to 20%. One of the critical elements of this exam is the measurement of fetal biometric parameters, which are the head circumference (HC), biparietal diameter (BPD), abdominal circumference (AC), and femur length (FL) measured on biometry standard planes. Those standard planes are taken according to quality standards first described by Salomon et al. and used as the guidelines of the International Society of Ultrasound in Obstetrics and Gynecology (ISUOG). The biometric parameters extracted from them are essential to diagnose fetal growth restriction (FGR), the world's first cause of perinatal fetal mortality. Such measurements and image quality assessment are time-consuming tasks that are prone to inter and intraobserver variability depending on the level of skill of the sonographer or the physician performing the exam. Amniotic fluid (AF) volume assessment is also an essential step in routine screening scans allowing the diagnosis of oligo or hydramnios, both associated with increased fetal mortality rates. The AF is measured by two main "semi-quantitative" techniques: Amniotic Fluid Index (AFI) and the single deepest pocket (SDP). The latter is more specific as it lowers the overdiagnosis of oligo-amnios without any impact on mortality or morbidity and is easier to perform for the sonographer (only one measurement versus four in the case of the AFI technique). However, AF assessment remains a time-consuming and poorly reproducible task. Attempts to automate such biometric measurements and AF volume assessment have been made using Artificial Intelligence (AI) and deep learning (DL) tools. Studies showed excellent results "in silico," reaching up to 98 %, 95%, 93 % dice score coefficients for HC, AC, and FL measurements and 89 % DSC for AFI measurements. However, they were all conducted retrospectively without validation on prospectively acquired images. Reviews and experts have stressed the need for quality peer-reviewed prospective studies to assess AI tools' performance with real-world data. Their performance is expected to be worse and to reflect better their use in the clinical workflow. This study aims to develop DL models to automate HC, BPD, AC, and FL measurements and AF volume assessment from retrospectively acquired data and test their performances to those of clinicians and experts on prospective real-world fetal US scans.

NCT ID: NCT05033509 Completed - Mortality Clinical Trials

Outcome of ECMO and CRRT.

Start date: January 1, 2019
Phase:
Study type: Observational

Background: Although acute kidney injury (AKI) is a frequent complication in patients receiving extracorporeal membrane oxygenation (ECMO), and the CRRT impact is widely studied. The incidence of simultaneous use of ECMO and CRRT remain unclear. Objective: The investigatore conducted this retrospective study to define the incidence of concomitant CRRT with ECMO therapy and to determine the overall impact of this strategy on patient outcomes such as mortality and renal recovery. Methods: The investigatore retrospectively analyzed data of patients of all ages, genders and ethnicities, admitted in the intensive care unit of Mohammed VI University Hospital, Oujda, Morocco, on a cumulative period of 2 years (January 2019 - December 2020). Were enrolled in the study patients who benefited from ECMO, and presented an acute kidney injury afterwards, using 'Microsoft Excel' as a software to utilize the information collected from the computerized patient database. 30 patients were included in the final study.

NCT ID: NCT05008016 Completed - Clinical trials for the Relationship Between Procalcitonin and 30-day Mortality in COVID Patients

Procalcitonin Level and the High Risk of Mortality in 30 Days in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Patient , Cases Series.

Start date: January 1, 2020
Phase:
Study type: Observational

Background: Procalcitonin (PCT) is a biomarker that has been proposed as a helpful tool in inflammatory Clinique cases specially patient with pulmonary bacterienne infection . Materials and methods the investigatore had retrospectively reviewed the electronic records and lists of all 582 COVID-19 patients admitted on the ICU of Hospital university Mohammed VI , Oujda. Between 01 juin 2020 and 31juanary 2021 , and analyzed the relation of PCT value and mortality at 30 days until we can defined a cut off Procalcitonine to use as a marker of severity and high mortality .

NCT ID: NCT04995289 Completed - Clinical trials for Hypoxemic Respiratory Failure

Prone Position During ECMO in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Hypoxaemic Patient

Start date: January 1, 2020
Phase:
Study type: Observational

Introduction: The main manifestation of COVID-19 pneumonia is acute respiratory distress syndrome (ARDS), which in some cases can be more severe than intubation, extracorporeal membrane venous oxygenation (VV-ECMO) to ensure hematosis. Despite support from VV-ECMO, some patients may remain hypoxemic. One possible therapeutic procedure for these patients is the application of the prone position. Objective: The main aim of this study was to investigate the modification of the PaO2/FiO2 ratio, the compliance of the respiratory system in VV-ECMO with refractory hypoxemia. The secondary objective was to evaluate the safety and feasibility of the inclined position for ECMO. Methods: the investigators reviewed the electronic records and lists of all 23 COVID-19 patients. were placed for the first time in PP with an average duration of 16 h . patient characteristics, pre-ECMO characteristics, ventilator/ECMO settings, and changes in ventilator/ECMO settings and blood gas analysis before and after PP.

NCT ID: NCT04963426 Recruiting - Healthy Clinical Trials

Empowering Adolescents to Lead Change Using Health Data

Start date: June 1, 2021
Phase: N/A
Study type: Interventional

This study is a cluster randomized trial carried out in schools of secondary cities of four low- and middle income countries. Baseline surveys in 30 randomly selected schools will assess the health behaviours of 13-17 year old students as well as school policies and practices. The intervention arm (15 schools) will use the baseline information to develop a package of actions in collaboration with students, teachers, and local authorities that will subsequently be implemented an monitored over two years. Follow-up surveys to evaluate the effectiveness of the implemented actions will be conducted after two years in all 30 previously selected schools.